RxDoctor Payments Data

Carl Hannah, MD

Family Medicine · Christiansburg, VANPI 1700848363

Payments from drug & device makers

$14,547in general payments, 2019–2025

Across 929 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • AbbVie$2K
  • AstraZeneca$1K
  • GSK$926
  • Pfizer$884
  • plus $7K from 45 others

What the payments were for

  • Food & beverage$14,26098%
  • Education$2872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,547 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$115,545
Medicare patients
272
Services billed
2,117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$162,816
TrulicityDulaglutide78$108,149
FarxigaDapagliflozin Propanediol61$91,922
MounjaroTirzepatide59$77,736
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$72,915
JardianceEmpagliflozin59$65,094
XareltoRivaroxaban62$55,811
EliquisApixaban59$53,979
MyrbetriqMirabegron46$35,278
Tresiba Flextouch U-200Insulin Degludec32$32,865
RybelsusSemaglutide15$24,291
JanuviaSitagliptin Phosphate20$19,321
Breo ElliptaFluticasone/Vilanterol14$12,408
Repatha SureclickEvolocumab20$12,102
SymbicortBudesonide/Formoterol Fumarate22$6,532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,603$187,107122 claims
Lilly USA, LLCTrulicity, Mounjaro$1,591$185,885137 claims
AstraZenecaFarxiga, Symbicort$1,134$98,45383 claims
GSKTrelegy Ellipta, Breo Ellipta$926$85,32385 claims
Boehringer IngelheimJardiance$692$65,09459 claims
Johnson & JohnsonXarelto$362$55,81162 claims
PfizerEliquis$884$53,97959 claims
Astellas Pharma US IncMyrbetriq$507$35,27846 claims
MerckJanuvia$300$19,32120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Christiansburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →